Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A

Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A

SSZSE:300702
20.57
CNY
+0.38
(+1.88%)
0.21EPS
113.73P/E
7.89BMarket Cap
Apr 16Next Earn

Total Valuation

CNY

As of September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A carries a market capitalization of 7.89B, placing it among publicly traded companies globally. Its enterprise value stands at 9.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.89B
Enterprise Value9.33B

Important Dates

Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A's next confirmed earnings release is scheduled for April 16, 2027.

Earnings Date4/16/2027

Share Statistics

As of September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A has 347.98M shares outstanding.

Shares Outstanding347.98M

Valuation Ratios

As of September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 113.73. The price-to-sales ratio is 2.08, and the price-to-book ratio stands at 2.19.

PE Ratio113.73
PS Ratio2.08
PB Ratio2.19
P/TBV Ratio2.57

Enterprise Valuation

As of September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A trades at an EV/EBITDA multiple of 83.89 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 83.89 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.33B versus a market cap of 7.89B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.46
EV / EBITDA83.89
EV / EBIT83.89

Financial Position

As of September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 51.88, indicating elevated leverage, while an interest coverage ratio of 2.71 demonstrates limited ability to service its debt obligations.

Current Ratio1.16
Quick Ratio0.19
Debt / Equity51.88
Debt / EBITDA17.01
Interest Coverage2.71

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A posted a return on equity (ROE) of 1.91, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.70 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.04, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.85, useful for judging operating efficiency across full business cycles. The company generates approximately 809,058.85 in revenue per employee across its workforce of 4,686.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.55 indicates how many times Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)1.91
Return on Assets (ROA)1.04
Return on Invested Capital (ROIC)1.70
Return on Capital Employed (ROCE)1.85
Revenue Per Employee809,058.85
Employee Count4,686.00
Inventory Turnover1.55

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A recorded 13.11M in income tax expense. That works out to an effective tax rate of 15.36, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 85.36M, leaving 69.26M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax13.11M
Effective Tax Rate15.36

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A's stock has declined approximately 22.26% over the past 52 weeks. The 50-day moving average sits at 20.96, while the 200-day moving average is 21.67.

52-Week Price Change-22.26%
50-Day Moving Average20.96
200-Day Moving Average21.67

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A generated 3.79B in revenue and converted that into 69.26M in net income, yielding earnings per share of 0.21. EBITDA reached 111.21M, while operating income came in at 258.59M.

Revenue3.79B
Gross Profit1.19B
Operating Income258.59M
Pretax Income85.36M
Net Income69.26M
EBITDA111.21M
EBIT111.21M
Earnings Per Share (EPS)0.21

Balance Sheet

CNY

As of September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A holds 498.25M in cash and equivalents against 1.89B in total debt, resulting in a net debt position of 1.25B. Total book value stands at 3.60B, with working capital of 411.00M providing operational flexibility.

Cash & Cash Equivalents498.25M
Total Debt1.89B
Net Debt1.25B
Equity (Book Value)3.60B
Book Value Per Share10.35
Working Capital411.00M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-337.42M

Margins

Over the twelve months ended September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A posted a gross margin of 31.27, reflecting its pricing power and cost economics. The operating margin of 6.82 and net profit margin of 1.83 provide insight into operational efficiency.

Gross Margin31.27
Operating Margin6.82
Pretax Margin2.25
Profit Margin1.83
EBITDA Margin2.93

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A paid dividends of 0.15 per share. The dividend payout ratio of 71.74 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 5.79, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A shareholders.

Dividend Per Share0.15
Payout Ratio71.74
Shareholder Yield5.79

Stock Splits

Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A's most recent stock split took place on June 18, 2021 with a 5:9 split ratio.

Last Split Date6/18/2021
Split Ratio5:9

Scores

As of September 30, 2026, Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A has an Altman Z-Score of 2.75, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.75